Comparison

CY-09 European Partner

Manufacturer MedChem Express
Category
Type Inhibitors
Specific against other
Amount 25mg
Item no. HY-103666-25mg
CASRN 1073612-91-5
Available
Product Description
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation.
StorageTemperature
Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
Applications
COVID-19-immunoregulation
Formula
C19H12F3NO3S2
References
[1].Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6; 214(11):3219-3238.
MolecularWeight
423.43
Research Area
Inflammation/Immunology
Solubility
DMSO : ≥ 150 mg/mL (354.25 mM) | H2O : < 0.1 mg/mL (insoluble)
Target
NOD-like Receptor (NLR)
Pathway
Immunology/Inflammation

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

Amount: 25mg
Available: In stock
available

Delivery expected until 4/20/2023 

Compare

Add to wishlist

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close